中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
35期
47-50
,共4页
肝肿瘤%肿瘤标记,生物学%早期诊断
肝腫瘤%腫瘤標記,生物學%早期診斷
간종류%종류표기,생물학%조기진단
Liver neoplasms%Tumor markers,biological%Early diagnosis
目的 探讨甲胎蛋白(AFP)、高尔基膜蛋白73 (GP73)、血管内皮细胞生长因子(VEGF)和α-L-岩藻糖苷酶(AFU)四项指标联合检测在原发性肝癌早期诊断与监控治疗中的临床应用价值.方法 采用电化学发光法、酶联免疫吸附法检测98例原发性肝癌患者(恶性肿瘤组)治疗前、治疗后3个月血清AFP、GP73、VEGF、AFU等免疫指标水平,与50例肝脏良性病变患者(良性对照组)及50例健康体检者(健康对照组)对照.结果 治疗前恶性肿瘤组血清AFP、GP73、VEGF、AFU水平分别为(219.16 ±56.89) μg/L、(355.42±109.26) μg/L、(88.21±24.22)μg/L、(276.51±83.20)U/L,良性对照组分别为(14.95±3.26)μg,/L、(56.43±15.72)μg/L、(2.68±1.27)μg/L、(25.38±11.17) U/L,健康对照组分别为(14.67±3.07)μg/L、(55.06±14.21)μg/L、(2.36±1.14) μ/L、(24.29±10.10) U/L,恶性肿瘤组与良性对照组和健康对照组比较差异有统计学意义(P＜ 0.01);治疗后恶性肿瘤组血清AFP等上述四项指标分别为(25.66±8.17) μg/L、(65.32±24.15) μ/L、(4.67±1.89)μg/L、(35.23±12.36) U/L,与治疗前比较差异有统计学意义(P＜0.01).四项肿瘤标记物联合检测诊断原发性肝癌敏感度为95.92％ (94/98)、准确度为93.24％(138/148),与各单项检测比较明显提高,差异有统计学意义(P＜0.05).结论 血清肿瘤标记物联合动态检测可作为原发性肝癌早期诊断和监控治疗的辅助手段.
目的 探討甲胎蛋白(AFP)、高爾基膜蛋白73 (GP73)、血管內皮細胞生長因子(VEGF)和α-L-巖藻糖苷酶(AFU)四項指標聯閤檢測在原髮性肝癌早期診斷與鑑控治療中的臨床應用價值.方法 採用電化學髮光法、酶聯免疫吸附法檢測98例原髮性肝癌患者(噁性腫瘤組)治療前、治療後3箇月血清AFP、GP73、VEGF、AFU等免疫指標水平,與50例肝髒良性病變患者(良性對照組)及50例健康體檢者(健康對照組)對照.結果 治療前噁性腫瘤組血清AFP、GP73、VEGF、AFU水平分彆為(219.16 ±56.89) μg/L、(355.42±109.26) μg/L、(88.21±24.22)μg/L、(276.51±83.20)U/L,良性對照組分彆為(14.95±3.26)μg,/L、(56.43±15.72)μg/L、(2.68±1.27)μg/L、(25.38±11.17) U/L,健康對照組分彆為(14.67±3.07)μg/L、(55.06±14.21)μg/L、(2.36±1.14) μ/L、(24.29±10.10) U/L,噁性腫瘤組與良性對照組和健康對照組比較差異有統計學意義(P＜ 0.01);治療後噁性腫瘤組血清AFP等上述四項指標分彆為(25.66±8.17) μg/L、(65.32±24.15) μ/L、(4.67±1.89)μg/L、(35.23±12.36) U/L,與治療前比較差異有統計學意義(P＜0.01).四項腫瘤標記物聯閤檢測診斷原髮性肝癌敏感度為95.92％ (94/98)、準確度為93.24％(138/148),與各單項檢測比較明顯提高,差異有統計學意義(P＜0.05).結論 血清腫瘤標記物聯閤動態檢測可作為原髮性肝癌早期診斷和鑑控治療的輔助手段.
목적 탐토갑태단백(AFP)、고이기막단백73 (GP73)、혈관내피세포생장인자(VEGF)화α-L-암조당감매(AFU)사항지표연합검측재원발성간암조기진단여감공치료중적림상응용개치.방법 채용전화학발광법、매련면역흡부법검측98례원발성간암환자(악성종류조)치료전、치료후3개월혈청AFP、GP73、VEGF、AFU등면역지표수평,여50례간장량성병변환자(량성대조조)급50례건강체검자(건강대조조)대조.결과 치료전악성종류조혈청AFP、GP73、VEGF、AFU수평분별위(219.16 ±56.89) μg/L、(355.42±109.26) μg/L、(88.21±24.22)μg/L、(276.51±83.20)U/L,량성대조조분별위(14.95±3.26)μg,/L、(56.43±15.72)μg/L、(2.68±1.27)μg/L、(25.38±11.17) U/L,건강대조조분별위(14.67±3.07)μg/L、(55.06±14.21)μg/L、(2.36±1.14) μ/L、(24.29±10.10) U/L,악성종류조여량성대조조화건강대조조비교차이유통계학의의(P＜ 0.01);치료후악성종류조혈청AFP등상술사항지표분별위(25.66±8.17) μg/L、(65.32±24.15) μ/L、(4.67±1.89)μg/L、(35.23±12.36) U/L,여치료전비교차이유통계학의의(P＜0.01).사항종류표기물연합검측진단원발성간암민감도위95.92％ (94/98)、준학도위93.24％(138/148),여각단항검측비교명현제고,차이유통계학의의(P＜0.05).결론 혈청종류표기물연합동태검측가작위원발성간암조기진단화감공치료적보조수단.
Objective To investigate the value on clinical application of dynamic and combined detection of serum tumor markers alpha-fetoprotein (AFP),Golgi protein 73 (GP73),vascular endothelial growth factor (VEGF) and alpha-L-fucosidase (AFU) in early diagnosis and monitoring treatment of primary hepatocellular carcinoma.Methods Serum levels of AFP,GP73,VEGF,AFU in 98 patients with primary hepatocellular carcinoma (the malignant group) before and 3 months after treatment were detected by electrochemiluminescence immunoassay and enzyme-linked immunosorbent assay,which compared with the levels of 50 liver benign lesions (the benign group) and 50 healthy subjects (the normal group).Results The levels of serum AFP,GP73,VEGF,AFU in the malignant group before treatment were (219.16 ± 56.89) μg/L,(355.42 ± 109.26) μg/L,(88.21 ±24.22) μg/L,(276.51 ±83.20) U/L.These indexes in the benign group were (14.95 ± 3.26) μ g/L,(56.43 ± 15.72) μ g/L,(2.68 ± 1.27) μ g/L,(25.38 ± 11.17)U/L.These indexes in the normal group were (14.67 ± 3.07) μ g/L,(55.06 ± 14.21) μ g/L,(2.36 ± 1.14) μ g/L,(24.29 ± 10.10) U/L.There were statistical differences between the malignant group and the benign group,normal group (P ＜ 0.01).The levels of these indexes after treatment in the malignant group were (25.66 ±8.17) μg/L,(65.32 ±24.15) μg/L,(4.67 ± 1.89) μg/L,(35.23 ± 12.36) U/L,there were statistical differences between before treatment and after treatment (P ＜ 0.01).The sensitivity and accuracy of combined detection of these tumor markers in diagnosis of primary hepatocellular carcinoma were 95.92％ (94/98) and 93.24％(138/148),which were statistically higher than single detection(P＜ 0.05).Conclusion The dynamic and combined detection of serum tumor markers could be applied as supplementary means in early diagnosis and monitoring treatment of primary hepatocellular carcinoma.
